6645 Stock Overview
Provides precision medical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Kim Forest Enterprise Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.85 |
| 52 Week High | NT$45.57 |
| 52 Week Low | NT$23.20 |
| Beta | -0.22 |
| 11 Month Change | 10.96% |
| 3 Month Change | -8.09% |
| 1 Year Change | -34.51% |
| 33 Year Change | 19.05% |
| 5 Year Change | 202.96% |
| Change since IPO | 54.88% |
Recent News & Updates
Shareholder Returns
| 6645 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 2.0% | -1.0% | 0.8% |
| 1Y | -34.5% | 0.7% | 30.3% |
Return vs Industry: 6645 underperformed the TW Biotechs industry which returned 0.7% over the past year.
Return vs Market: 6645 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6645 volatility | |
|---|---|
| 6645 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6645 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6645's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Daniel Huang | www.kimforest.com |
Kim Forest Enterprise Co., Ltd. provides precision medical products. It offers devices, reagents, and analysis pipelines to health care providers, which include screening tests for cancer and inherited diseases. The company also provides genetic testing, drug report, and monitoring tools for cancer patients; and a non-invasive genome-wide health assessment for healthy persons.
Kim Forest Enterprise Co., Ltd. Fundamentals Summary
| 6645 fundamental statistics | |
|---|---|
| Market cap | NT$1.53b |
| Earnings (TTM) | -NT$153.32m |
| Revenue (TTM) | NT$472.82m |
3.2x
P/S Ratio-10.0x
P/E RatioIs 6645 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6645 income statement (TTM) | |
|---|---|
| Revenue | NT$472.82m |
| Cost of Revenue | NT$417.88m |
| Gross Profit | NT$54.94m |
| Other Expenses | NT$208.27m |
| Earnings | -NT$153.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.79 |
| Gross Margin | 11.62% |
| Net Profit Margin | -32.43% |
| Debt/Equity Ratio | 49.3% |
How did 6645 perform over the long term?
See historical performance and comparison